Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study

In this large real-world cohort, bevacizumab-based therapy achieved meaningful disease control and survival in recurrent primary brain tumors. An irinotecan-bevacizumab regimen administered every 14 days was associated with superior OS at the expense of increased but manageable chemotherapy-related toxicity, supporting its use in appropriately selected patients.

Authors

Institutions

Publication Details

Journal
BMC Cancer
Published
2026-02-14
DOI
https://doi.org/10.1186/s12885-026-15725-9
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study

Selver Işık, Fatih Teker, Seda Kahraman, Necla Demir et al.
BMC Cancer
Glioma Diagnosis and Treatment
article

Evaluation of the efficacy and tolerability of bevacizumab-based treatments in recurrent primary brain tumors: a multicenter real-world Turkish Oncology Group (TOG) study

Selver Işık, Fatih Teker, Seda Kahraman, Necla Demir, Şener CİHAN, Kayhan Ertürk, Meral Günaldı, Ahmet Gülmez, Teoman Şakalar, Derya Demirtas Esmer, Fatma Paksoy Türköz, Asude Aksoy, Gökhan Karakaya, Esra Zeynelgil, Hacı Mehmet Türk, Melek Karakurt Eryılmaz, Engin Kut, Serdar Turhal, Eda Çalışkan Yıldırım, Ozkan Alan, Özlem Özkul, Özgecan Dülgar, Leyla Özer, Feride Yılmaz, Sema Türker, Emir Çelik, Nilay Şengül, Şaban Seçmeler, Zehra Sucuoğlu İşleyen, M. Mustafa Atcı, Fatih Karataş
article en

Abstract

In this large real-world cohort, bevacizumab-based therapy achieved meaningful disease control and survival in recurrent primary brain tumors. An irinotecan-bevacizumab regimen administered every 14 days was associated with superior OS at the expense of increased but manageable chemotherapy-related toxicity, supporting its use in appropriately selected patients.

BMC CancerVol. 26(1)
Bahçeşehir University (TR), Anadolu University (TR), Karabük University (TR), Dokuz Eylül University (TR), Nicosia General Hospital (CY), Bezmiâlem Vakıf Üniversitesi (TR), Istanbul Medipol University (TR), Memorial Ankara Hospital (TR), Necmettin Erbakan University (TR), Ümraniye Eğitim ve Araştırma Hastanesi (TR), Memorial Sisli Hospital (TR), Istanbul University-Cerrahpaşa (TR), Samsun University (TR), Botkin Hospital (RU), Istinye University (TR), Istanbul Eye Hospital (TR), Ankara Yıldırım Beyazıt University (TR), Liv Hospital (TR), Acıbadem Adana Hospital (TR), Antalya IVF (TR), İstanbul Kanuni Sultan Süleyman Eğitim ve Araştırma Hastanesi (TR), Maltepe University (TR), Kahramanmaraş Sütçü İmam University (TR), Istanbul University (TR), Marmara University (TR)
Good health and well-being
Openalex Percentile: Top 55%
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.